secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261799
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan reports Phase 1 CLN-049 data: 31% CRc at 12 μg/kg in r/r AML
---------------------------------------------------------------------

- Anti-leukemic activity at doses ≥6 μg/kg: CRc 30%, ORR 57% (n=23); at 12 μg/kg CRc 31%, ORR 69% (n=13).
- Responses across genetic risk; in TP53-mutated AML 4/5 patients responded (2 CRh, 2 MLFS) at 12 μg/kg.
- Safety manageable: all CRS Grade 1-2; no discontinuations due to CRS or ICANS. Common TEAEs: CRS 40%, IRR 35%.
- Oral presentation at ASH on Dec 8, 2025; dose escalation ongoing. Company to host investor event Dec 8.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312525261799/0001193125-25-261799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312525261799/cgem-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer